SEANGWORLD FACT BRIEF · SEANGWORLDNEWS · 1 SOURCE
FDA issues guidance to maintain supply of neonatal starter parenteral nutrition
The U.S. Food and Drug Administration announced temporary regulatory and enforcement policies for compounding neonatal starter parenteral nutrition (PN) drug products to help address a potential supply gap caused by the closure of two outsourcing facilities. These products provide essential nutrients intravenously to premature and critically ill newborns who cannot be fed orally or through feeding tubes. The FDA's guidance aims to support hospitals in maintaining access to these life-saving nutrition products while longer-term solutions are developed. The agency will continue monitoring supply needs and assessing if further action is necessary.
Published ET · Updated ET
Corroboration
Single source · 1 SOURCE
This story cluster currently contains one independent publisher.
Source count is a transparency signal, not a truth score. Read Our Method.
Facts
- Established fact
The FDA announced it is taking action to help address a potential supply gap of neonatal starter parenteral nutrition.
- Established fact
Two outsourcing facilities that made certain standardized neonatal starter PN products are permanently shutting down.
- Established fact
The FDA issued immediately-in-effect guidance titled 'Temporary Policies for Compounding Certain Starter Parenteral Nutrition Drug Products for Neonates' describing temporary regulatory and enforcement priorities.
- Established fact
Neonatal starter parenteral nutrition provides essential nutrients through an IV to premature and critically ill newborns who cannot receive nutrition orally or via feeding tube.
- Established factActing FDA Commissioner Kyle Diamantas
The FDA is working with healthcare providers and industry partners to ensure continued access to neonatal starter PN products.
- Established fact
The FDA will continue to monitor supply needs and assess if additional action is needed.
What changed
The FDA issued immediately-in-effect guidance describing temporary regulatory and enforcement priorities for compounding neonatal starter PN drug products.
Who is affected
Hospitals, state-licensed pharmacies, federal facilities, and outsourcing facilities involved in compounding neonatal starter PN products.
What happens next
The FDA will continue to monitor supply and may take additional actions if needed.
Sources
1 SOURCE